CONTROLLING THE ENVIRONMENTAL IMPACT OF ITS ACTIVITIES
LFB takes concrete action to control the environmental impact of its activities. The Group implements various environmental policies aimed at its employees, service providers, clients, suppliers, etc.
A policy to reduce the packaging used for LFB medicinal product transport was introduced in 2009. Through the use of refrigerated trucks, it prevents several tonnes of packaging from being generated each year.
LFB employees receive training on Corporate Social Responsibility (CSR) and environmental protection. Induction and orientation sessions for new employees cover LFB’s actions to reduce the environmental impact of its activities.
LFB also implemented a Corporate Travel Plan (CTP) for its employees. The plan includes a new online carpooling application, in addition to the carpooling plan that is already in place. In order to reduce LFB’s second largest source of greenhouse gas emission, national and international business travel was limited and all LFB meeting rooms were equipped with video conferencing.
Also with a view to diminishing its environmental impact, LFB’s paper consumption since 2013 has been contained, and the printer/copier fleet was reduced and replaced by “all-in-one” fax machines. The paper used at LFB is certified by the FSC (Forest Stewardship Council), meaning that it is made using responsibly sourced wood fibre. A life cycle analysis (LCA) of the paper used by LFB was conducted: it demonstrated that the paper is EU Ecolabel compliant.
An internet health portal, intended for LFB clients, was developed and made available to both public and private healthcare establishments: it facilitates order processing and follow-up, thus enabling the dematerialisation of purchase orders.
RESULTS RELATED TO MANUFACTURING PRACTICES AND THEIR ENVIRONMENTAL IMPACT
As an international industrial manufacturer with five bioproduction sites (four of which are located France), LFB is committed to decreasing energy and water consumption and reducing waste material production. Water is an important resource, and LFB medicinal product manufacturing processes rely on its use. New CO2 technology is used to treat the effluents generated as a result of these processes. French bioproduction sites have been using this technology since 2016. Not only does CO2 technology have less of an impact on the environment, it is also more economical. Hazardous and non-hazardous waste is sorted and processed by dedicated suppliers, and their tonnage has remained stable since 2016.
Direct CO2 emissions from LFB sites decreased by 13% between 2011 and 2017. This decrease was implemented to help the Group further reduce its 2030 CO2 emissions by 40%, as stipulated in the Energy Transition Act of 17 August 2015.
LFB currently has a contract with its electricity supplier, guaranteeing that 25% of the electrical energy consumed by LFB sites in France is from renewable sources.